Adjunctive Dexmedetomidine in Alcohol Withdrawal Syndrome: A Systematic Review and Meta-analysis of Retrospective Cohort Studies and Randomized Controlled Trials

Abstract

Objective:

To investigate whether dexmedetomidine (DEX), as adjunctive therapy to benzodiazepine (BZD), is superior to BZD alone in critically ill patients with alcohol withdrawal syndrome (AWS).

Data Sources:

PubMed Central, Cochrane CENTRAL, ClinicalTrials.gov and Google Scholar were used as search databases. Specific keywords and MeSH terms were “dexmedetomidine,” “benzodiazepine,” and “alcohol withdrawal syndrome.” The last search was on September 16, 2022.

Study Selection and Data Extraction:

Randomized controlled trials (RCTs) and nonrandomized/cohort studies exploring the use of DEX in the management of AWS were included. A total of 12 studies were included in the systematic review and 7 in the meta-analysis.

Data Synthesis:

The intensive care unit length of stay (ICU LOS) was found to have a mean difference (MD) of 48.06 [37.48, 58.64], P = <0.001 for the cohort subgroup, significantly favoring the DEX arm, but, in contrast, pooled RCT data showed a result of –20.07 [–36.86, –3.28], P = 0.02, a shorter ICU LOS for the DEX arm. Bradycardia and hypotension incidence significantly favored the BZD arm in both subgroups. This study compares the effectiveness of adjunctive DEX in clinical practice and aims to help providers in critical decision-making by compiling and analyzing the best current available evidence of its use in AWS.

Conclusions:

Based on low to very low level of evidence, adjunctive DEX showed no significant difference for ICU LOS when compared with BZD alone. Pooled randomized trials potentially show a benefit but are similarly limited by their low quality of evidence.

Keywords

alcohol intoxication benzodiazepines drug alcohol and substance abuse adrenergic agonists substance abuse

Get full access to this article

View all access options for this article.

References

National Institute on Alcohol Abuse and Alcoholism. Alcohol facts and statistics. National Institutes of Health. Published 2020. Accessed September 26, 2022. https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/alcohol-facts-and-statistics.

Goodson

Clark

Douglas

. Predictors of severe alcohol withdrawal syndrome: a systematic review and meta-analysis. Alcohol Clin Exp Res. 2014;38(10):2664-2677. doi:10.1111/acer.12529.

Salottolo

McGuire

Mains

van Doorn

Bar-Or

. Occurrence, predictors, and prognosis of alcohol withdrawal syndrome and delirium tremens following traumatic injury. Crit Care Med. 2017;45(5):867-874. doi:10.1097/CCM.0000000000002371.

Pace

. Alcohol withdrawal: epidemiology, clinical manifestations, course, assessment, and diagnosis. UptoDate. Date unknown. Accessed September 26, 2022. https://www.uptodate.com/contents/alcohol-withdrawal-epidemiology-clinical-manifestations-course-assessment-and-diagnosis.

Tsai

Gastfriend

Coyle

. The glutamatergic basis of human alcoholism. Am J Psychiatry. 1995;152(3):332-340. doi:10.1176/ajp.152.3.332.

Morrow

Suzdak

Karanian

Paul

. Chronic ethanol administration alters gamma-aminobutyric acid, pentobarbital and ethanol-mediated 36Cl-uptake in cerebral cortical synaptoneurosomes. J Pharmacol Exp Ther. 1988;246(1):158-164.

Schuckit

. Recognition and management of withdrawal delirium (delirium tremens). N Engl J Med. 2014;371(22):2109-2113. doi:10.1056/NEJMra1407298.

Mayo-Smith

Beecher

Fischer

, et al. Management of alcohol withdrawal delirium. An evidence-based practice guideline. [published correction appears in Arch Intern Med. 2004;164(18):2068] Arch Intern Med. 2004;164(13):1405-1412. doi:10.1001/archinte.164.13.1405.

Wang

Chen

Tang

, et al. Benzodiazepines associated with acute respiratory failure in patients with obstructive sleep apnea. Front Pharmacol. 2019;9:1513. doi:10.3389/fphar.2018.01513.

10.

Fukasawa

Suzuki

Otani

. Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther. 2007;32(4):333-341. doi:10.1111/j.1365-2710.2007.00829.x.

11.

Cagetti

Liang

Spigelman

Olsen

. Withdrawal from chronic intermittent ethanol treatment changes subunit composition, reduces synaptic function, and decreases behavioral responses to positive allosteric modulators of GABAA receptors. Mol Pharmacol. 2003;63(1):53-64.

12.

Langlois

Cormier

Villeneuve

Hoffman

Longo

Gosselin

. Benzodiazepine resistant alcohol withdrawal: what is the clinician’s preferred definition? CJEM. 2020;22(2):165-169. doi:10.1017/cem.2019.421.

13.

Dixit

Endicott

Burry

, et al. Management of acute alcohol withdrawal syndrome in critically ill patients. Pharmacotherapy. 2016;36(7):797-822. doi:10.1002/phar.1770.

14.

Precedex (dexmedetomidine hydrochloride) injection [package insert]. Lake Forest, IL: Hospira, Inc; 2010.

15.

Woods

Giometti

Weeks

. The use of dexmedetomidine as an adjuvant to benzodiazepine-based therapy to decrease the severity of delirium in alcohol withdrawal in adult intensive care unit patients: a systematic review. JBI Database System Rev Implement Rep. 2015;13(1):224-252. doi:10.11124/jbisrir-2015-1602.

16.

Glahn

Proskynitopoulos

Bleich

Hillemacher

. Pharmacotherapeutic management of acute alcohol withdrawal syndrome in critically Ill patients. Expert Opin Pharmacother. 2020;21(9):1083-1092. doi:10.1080/14656566.2020.1746271.

17.

Beg

Fisher

Siu

Rajan

Troxell

Liu

. Treatment of alcohol withdrawal syndrome with and without dexmedetomidine. Perm J. 2016;20(2):49-53. doi:10.7812/TPP/15-113.

18.

Crispo

Daley

Pepin

Harford

Brown

. Comparison of clinical outcomes in nonintubated patients with severe alcohol withdrawal syndrome treated with continuous-infusion sedatives: dexmedetomidine versus benzodiazepines. Pharmacotherapy. 2014;34(9):910-917. doi:10.1002/phar.1448.

19.

Guyatt

Oxman

Akl

, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-394. doi:10.1016/j.jclinepi.2010.04.026.

20.

Rosner

. Chapter 7: Hypothesis testing: categorical data/estimation of sample size and power for comparing two binomial proportions. In: Taylor M, Seibert D, Walsh S, eds. Fundamentals of Biostatistics. 7th ed. Brooks/Cole, Boston; 2011: 381-389.

21.

Paez

. Gray literature: an important resource in systematic reviews. J Evid Based Med. 2017;10(3):233-240. doi:10.1111/jebm.12266.

22.

Mertz

Loeb

. Newcastle-Ottawa Scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol. 2014;14:45. doi:10.1186/1471-2288-14-45.

23.

Higgins

JPT

Sally

Green

. Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0). London, England: Cochrane Group; 2011. Accessed September 26, 2022. https://handbook-5-1.cochrane.org/front_page.htm.

24.

Luo

Wan

Liu

Tong

. Optimally estimating the sample mean from the sample size, median, mid-range and/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785-1805.

25.

Shi

Luo

Weng

, et al. Optimally estimating the sample standard deviation from the five-number summary. Res Synth Methods. 2020;11(5):641-654.

26.

Review Manager (RevMan) [Computer program], Version 5.4. London, England: The Cochrane Collaboration; 2020.

27.

StataCorp. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC; 2021.

28.

Shi

Luo

Wan

, et al. Detecting the skewness of data from the sample size and the five-number summary. arXiv preprint arXiv:2010.05749.

29.

Lizotte

Kappes

Bartel

Hayes

Lesselyoung

. Evaluating the effects of dexmedetomidine compared to propofol as adjunctive therapy in patients with alcohol withdrawal. Clin Pharmacol. 2014;6:171-177. doi:10.2147/CPAA.S70490.

30.

Terra

Thomas

. 821: Effect of dexmedetomidine on ICU length of stay in the setting of severe alcohol withdrawal. Crit Care Med. 2020;48(1):390.

31.

Stefanilo, Catherine

. Dexmedetomidine Use in Alcohol Withdrawal Syndrome: A Retrospective Chart Review [Master’s theses Graduate research and major papers overview];2020. Accessed September 26, 2022. https://digitalcommons.ric.edu/cgi/viewcontent.cgi?article=1374&context=etd.

32.

Ludtke

Stanley

Yount

Gerkin

. Retrospective review of critically ill patients experiencing alcohol withdrawal: dexmedetomidine versus propofol and/or lorazepam continuous infusions. Hosp Pharm. 2015;50(3):208-213. doi:10.1310/hpj5003-208.

33.

Love

Zimmermann

. Use of propofol plus dexmedetomidine in patients experiencing severe alcohol withdrawal in the intensive care unit. J Clin Pharmacol. 2020;60(4):439-443. doi:10.1002/jcph.1539.

34.

Collier

Farrell

Killian

Kataria

. Effect of adjunctive dexmedetomidine in the treatment of alcohol withdrawal compared to benzodiazepine symptom-triggered therapy in critically ill patients: the EvADE study. J Pharm Pract. 2022;35(3):356-362. doi:10.1177/0897190020977755.

35.

Yavarovich

Bintvihok

McCarty

Breeze

LaCamera

. Association between dexmedetomidine use for the treatment of alcohol withdrawal syndrome and intensive care unit length of stay. J Intensive Care. 2019;7:49. doi:10.1186/s40560-019-0405-1.

36.

VanderWeide

Foster

MacLaren

Kiser

Fish

Mueller

. Evaluation of early dexmedetomidine addition to the standard of care for severe alcohol withdrawal in the ICU: a retrospective controlled cohort study. J Intensive Care Med. 2016;31(3):198-204. doi:10.1177/0885066614554908.

37.

Bielka

Kuchyn

Glumcher

. Addition of dexmedetomidine to benzodiazepines for patients with alcohol withdrawal syndrome in the intensive care unit: a randomized controlled study. Ann Intensive Care. 2015;5(1):33. doi:10.1186/s13613-015-0075-7.

38.

Mueller

Preslaski

Kiser

, et al. A randomized, double-blind, placebo-controlled dose range study of dexmedetomidine as adjunctive therapy for alcohol withdrawal. Crit Care Med. 2014;42(5):1131-1139. doi:10.1097/CCM.0000000000000141.

39.

Rovasalo

Tohmo

Aantaa

Kettunen

Palojoki

. Dexmedetomidine as an adjuvant in the treatment of alcohol withdrawal delirium: a case report. Gen Hosp Psychiatry. 2006;28(4):362-363. doi:10.1016/j.genhosppsych.2006.03.002.

40.

Darrouj

Puri

Prince

Lomonaco

Spevetz

Gerber

. Dexmedetomidine infusion as adjunctive therapy to benzodiazepines for acute alcohol withdrawal. Ann Pharmacother. 2008;42(11):1703-1705. doi:10.1345/aph.1K678.

41.

Linn

Loeser

. Dexmedetomidine for alcohol withdrawal syndrome. Ann Pharmacother. 2015;49(12):1336-1342. doi:10.1177/1060028015607038.

42.

Rayner

Weinert

Peng

Jepsen

, Broccard AF; Study Institution. Dexmedetomidine as adjunct treatment for severe alcohol withdrawal in the ICU. Ann Intensive Care. 2012;2(1):12. doi:10.1186/2110-5820-2-12.

43.

Frazee

Personett

Leung

Nelson

Dierkhising

Bauer

. Influence of dexmedetomidine therapy on the management of severe alcohol withdrawal syndrome in critically ill patients. J Crit Care. 2014;29(2):298-302. doi:10.1016/j.jcrc.2013.11.016.

44.

Singal

Higgins

Waljee

. A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol. 2014;5(1):e45. doi:10.1038/ctg.2013.13.

45.

Kaur

Singh

. Current role of dexmedetomidine in clinical anesthesia and intensive care. Anesth Essays Res. 2011;5(2):128-133. doi:10.4103/0259-1162.94750.

46.

Dexmedetomidine for sedation in the ICU or PICU: a review of cost-effectiveness and guidelines . Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2014.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB

0.01 MB

0.20 MB

1.26 MB

4.23 MB

0.21 MB

0.23 MB